CRISPR Therapeutics AG [CRSP] stock is trading at $57.84, up 2.81%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRSP shares have gain 6.91% over the last week, with a monthly amount drifted -1.67%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on February 14, 2025, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $99 from $60. Previously, TD Cowen upgraded its rating to Hold on February 12, 2025, and kept the price target unchanged to $35. On February 03, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $65 on the stock. Needham reiterated its Buy rating and decreased its price target to $84 on August 06, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $90 as its price target on August 02, 2024. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
CRISPR Therapeutics AG [CRSP] stock has fluctuated between $30.04 and $71.13 over the past year. Currently, Wall Street analysts expect the stock to reach $99.31 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $57.84 at the most recent close of the market. An investor can expect a potential return of 71.7% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
CRISPR Therapeutics AG [NASDAQ:CRSP] reported sales of 38.05M for the trailing twelve months, which represents a growth of 72.53%. Gross Profit Margin for this corporation currently stands at -2.17% with Operating Profit Margin at -12.21%, Pretax Profit Margin comes in at -12.42%, and Net Profit Margin reading is -12.52%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.25 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, CRISPR Therapeutics AG’s Current Ratio is 16.61. As well, the Quick Ratio is 16.61, while the Cash Ratio is 1.89. Considering the valuation of this stock, the price to sales ratio is 138.25, the price to book ratio is 2.99.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Aug 18 ’25 when 13081.0 shares were sold. Director, Treco Douglas A completed a deal on Aug 06 ’25 to buy 20000.0 shares. Meanwhile, Director George Simeon bought 0.99 million shares on Jul 16 ’25.
